NCT00095459View on ClinicalTrials.gov

BAY 43-9006 (Sorafenib) and Bevacizumab (Avastin) To Treat Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

November 2, 2004

Primary Completion Date

November 1, 2005

Study Completion Date

July 20, 2012

Conditions
Neoplasms
Interventions
DRUG

Bevacizumab

DRUG

BAY 43-9006

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00095459 - BAY 43-9006 (Sorafenib) and Bevacizumab (Avastin) To Treat Solid Tumors | Biotech Hunter | Biotech Hunter